Accent Therapeutics, a clinical-stage biopharmaceutical company, is at the forefront of developing small molecule precision cancer therapies targeting critical intracellular dependencies across various cancer types. Leveraging expertise in RNA-modifying proteins (RMPs) and strategic mapping of the RMP space, the company is focused on creating biomarker-driven cancer medicines that could revolutionize oncology treatments. Accent’s lead programs, […]